Download the BioTrinity 2015 Preliminary Programme here

BioTrinity 2015 - European Biopartnering and Investment Conference - May 11-13, 2015

Where Great MindsSmart Money and Key Dealmakers Meet

BioTrinity is the leading European Biopartnering and Investment Conference.  It provides the best opportunity to meet investors, senior licensing executives from global pharma organisations and senior management of innovative drug development and platform technology companies.

Now in its 9th year, BioTrinity is expected once again to attract 1000+ delegates from over 30 countries. The new, dedicated MediTrinity stream will attract key personnel from medtech corporates and diagnostics R&D companies.

At the heart of the event are the world class speaker programme, compelling panels of experts and the powerhouse partnering system.  Together with the unequalled networking opportunities for emerging companies to pitch for partners and investment, BioTrinity has become the best catalyst for business for R&D, pharma and medtech corporates:

  • Discover essential trends and ideas from the key players in the pharma and investment world
  • Hear insight into securing investment through venture, corporate and strategic funds from leading minds in the global life sciences investment
  • Be inspired by some of pharma’s hottest dealmakers offering a fresh perspective on successful dealmaking strategies
  • Take your pick of over 100 of Europe’s best life sciences R&D company showcase sessions
  • Gain invaluable up-to-date advice in your choice of industry workshops
  • Design your opportunities – select who you want to meet in one-to-one meetings through partneringONE®

In 2014 we hosted 2,462 one-to-one meetings over two days between 1,014 delegates from 32 countries, representing more than 624 companies.

Last year licensing contacts from large corporates included AbbVie, Amgen, Astellas, AstraZeneca, Boehringer, Bristol-Myers Squibb, Chiesi, Eli Lilly, Genzyme, GE, GlaxoSmithKline, Johnson & Johnson, Life Technologies, Linde AG, MSD, Novartis, Novo Nordisk, Sanofi-Aventis, Sanofi-Pasteur, Shire, Pfizer, Roche, Takeda as well as mid-sized including Vertex, Ferrer, Actelion, MorphoSys, Nordic Pharma, Norgine, Qiagen, QuantuMDx, and other senior BD&L executives.

Over 100 delegates from active VC and Corporate Venture firms included MedImmune Ventures, SR One, Johnson & Johnson Development Corporation, AbbVie Inc, Mitsui & Co, MPH Ventures, Norgine Ventures, Novartis Venture Fund, MS Ventures, MRL Venture Fund, Takeda Ventures, Unilever Ventures, Boehringer Ingelheim Ventures, Inventages, as well as Lundbeckfond Ventures, Novo A/S, Syncona, Index, Sofinnova, EdRIP and many international VCs.

Thanks to EBD Group's partneringONE®, the industry gold-standard partnering system with entirely private partnering: 


You need to upgrade your Flash Player

The "Event of the Year" - BioTrinity 2014:

Huge partnering potential with global pharma / investors

 100 presentations by hand-picked R&D companies

 Innovative "Connect for Growth" zones that encouraged informal and formal collaborative interactions

Great networking opportunities with 1000 delegates

 First class venue at Novotel London West

Exciting Social Programme:

 The Big London Networking Party, BioTrinity Welcome Reception and Connect for Drinks

 Europe's Largest Investor-only Dinner

Check out the glowing testimonials we received for BioTrinity, or view the photos from the Gallery

BioTrinity 2014 highlights
1,014 delegates from 32 countries
624 companies
184 speakers
107 company showcase presentations
2,462 one-to-one meetings
130+ investor delegates from 12 countries
61 exhibitors
86 global pharma/medtech delegates
33 corporate venture delegates